Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

Table 2 Univariate and multivariate analysis of overall survival, progression-free survival

	Overall survival						Progression-free survival
	Univariate			Multivariate			Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
Age (yr)
< 65	1						1
≥ 65	1.08	0.84-1.39	0.557				0.97	0.75-1.24	0.786
Sex
Female	1						1
Male	1.12	0.86-1.46	0.406				1.08	0.83-1.39	0.573
ECOG
0-1	1			1			1
≥ 2	1.5	1.10-2.03	0.009	1.40	1.00-1.97	0.050	1.23	0.81-0.91	0.173
Stage
Locally advanced	1			1			1			1
Metastatic	1.84	1.13-2.98	0.014	2.17	1.28-3.69	0.004	1.95	1.23-3.09	0.005	1.91	1.16-3.15	0.011
Differentiation
Well to moderately	1			1			1
Poorly	1.35	1.04-1.74	0.026	1.48	1.11-1.96	0.007	1.06	0.82-1.36	0.662
Biliary stent
No	1						1
Yes	0.98	0.66-1.46	0.939				0.81	0.55-1.20	0.297
Liver metastasis
No	1			1			1			1
Yes	1.25	0.98-1.61	0.077	1.22	0.93-1.60	0.135	1.51	1.19-1.93	0.001	1.54	1.19-2.01	0.001
Chemotherapy
Gemcitabine single	1			1			1			1
Other regimens	0.68	0.52-0.89	0.004	0.70	0.53-0.93	0.015	0.78	0.60-1.01	0.062	0.86	0.65-1.14	0.303
Pretreatment NLR
< 2.60	1			1			1			1
≥ 2.60	1.77	1.37-2.29	< 0.001	1.09	0.81-1.48	0.545	1.61	1.26-2.07	< 0.001	1.03	0.78-1.36	0.816
Post-treatment NLR
< 2.62	1			1			1			1
≥ 2.62	2.42	1.87-3.14	< 0.001	2.47	1.84-3.32	< 0.001	2.51	1.93-3.26	< 0.001	2.59	1.94-3.47	< 0.001
CA19-9 reduction
< 18%	1			1			1			1
≥ 18%	0.53	0.41-0.69	< 0.001	0.51	0.39-0.67	< 0.001	0.54	0.46-0.75	< 0.001	0.6	0.47-0.78	< 0.001
CEA (ng/mL)
≤ 5	1			1			1			1
> 5	1.27	0.98-1.65	0.066	1.20	0.91-1.57	0.187	1.26	0.98-1.62	0.074	1.17	0.90-1.52	0.231

Univariate analysis and multivariate survival analysis were performed using Cox proportional hazard model, and P values < 0.05 were considered to indicate statistical significance. Significant values are in boldface type. CI: Confidence interval; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil-to-lymphocyte ratio; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.